Drooid Logo
Back to story perspectives

Full Breakdown

Trump Family Business Ventures Raise Ethical Concerns

1/15/2026, 11:56:50 PM

Overview of Business Appointments

Following the 2024 presidential election, Donald Trump Jr. has been appointed to the boards and advisory boards of several companies, including Unusual Machines, Credova, BlinkRx, PublicSquare, GrabAGun, and Colombier Acquisition Corp. III. These appointments have coincided with significant business developments that suggest potential benefits from his father's administration. Notably, Unusual Machines received a substantial order from the U.S. Army shortly after Don Jr. joined its advisory board, raising questions about conflicts of interest.

Key Developments and Benefits

Unusual Machines, a drone manufacturer, appointed Don Jr. to its advisory board in late 2024, leading to a surge in its stock price. The company subsequently secured a government contract for 3,500 drone motors, with plans for additional orders. Credova, a subsidiary of PublicSquare, saw the closure of a Consumer Financial Protection Bureau (CFPB) investigation shortly after Don Jr. joined its board. This investigation had previously raised concerns about consumer protection violations. In 2025, Don Jr. was compensated over $3.1 million by Credova's parent company, which also provides financing for GrabAGun, an online gun retailer he supports.

BlinkRx, a digital pharmacy company, appointed Don Jr. to its board in February 2025. Shortly thereafter, President Trump initiated a program to facilitate direct-to-consumer drug sales, with BlinkRx positioned to play a role in this initiative. The company was also involved in organizing a summit that included government officials, further intertwining its operations with the administration's healthcare agenda.

Criticism and Ethical Concerns

The rapid expansion of business roles for Donald Trump Jr. and his brother Eric Trump has drawn scrutiny regarding potential conflicts of interest. Critics argue that these appointments create an appearance of preferential treatment, undermining public trust in government processes. While investigations have not confirmed explicit quid pro quo arrangements, the timing of business successes relative to their appointments raises ethical questions.

Democratic leaders in health committees have expressed concerns about possible coordination between the Trump administration and BlinkRx, questioning the integrity of government decision-making in light of these developments. In response, BlinkRx stated that it had no involvement in the development of the TrumpRx initiative, claiming to have learned about it through media reports.

Conclusion and Implications

The involvement of Donald Trump Jr. in multiple companies post-election highlights a potential intersection of business interests and government influence. As he and Eric Trump take on various roles, the implications for public trust and ethical governance remain significant. The situation underscores the need for transparency and accountability in the relationship between political figures and private enterprises, particularly when government contracts and regulatory decisions are at stake.

Verbatim Quotes

  • “’s role with Unusual Machines, CEO Allan Evans said, “[j]ust lending some of that association has created more credibility to rise above the noise.” — Allan Evans, CEO of Unusual Machines
  • “exemplifies the type of weaponization against disfavored industries and individuals that President Trump and Acting Director Vought are committed to ending.” — CFPB Official
  • “BlinkRx responded in a letter that the company first learned about TrumpRx “from press reports” and had “no role in the development” of the announcement.” — BlinkRx Representative